France has agreed to provide temporary funding to help a clinical trial of an experimental therapy for glioblastoma, a notoriously hard-to-treat form of brain cancer, to go ahead.
Bristol-Myers Squibb has ended a $3.1 billion strategic collaboration with Eisai focusing on antibody-drug conjugates (ADCs) and returned rights to the lead drug in the alliance.
The FDA has said it cannot approve MSD and Daiichi Sankyo’s HER3-targeted antibody-drug conjugate (ADC) patritumab deruxtecan because of problems at a third-party manufacturer.
AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladde
Two years ago, Merck KgAA was talking up xevinapant as a leap forward in head and neck cancer and one of the brightest stars in its late-stage pipeline, Now, the drug has been abandoned aft
Daiichi Sankyo has a second approval in Japan for Ezharmia, its first-in-class dual EZH1 and EZH2 inhibitor, as a treatment for relapsed or refractory peripheral T-cell lymphoma (PTCL).